Here, we utilised a polytherapy approach to investigate if using a combination of CuATSM, ebselen and telbivudine, provides increased beneficial outcomes compared to the established therapeutic properties of CuATSM monotherapy in various SOD1 ALS models. Here, SOD1 is linked to amyotrophic lateral sclerosis.